Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.54, for a total value of $23,816.00.
• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total value of $21,568.00.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded up $1.86 during trading on Monday, hitting $64.35. 334,305 shares of the stock were exchanged, compared to its average volume of 238,236. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -117.00 and a beta of 0.63. The company has a fifty day moving average price of $58.59 and a 200-day moving average price of $58.07. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Remove Ads

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its position in ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after acquiring an additional 473,097 shares during the last quarter. State Street Corp increased its stake in shares of ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock worth $41,991,000 after purchasing an additional 58,698 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 4.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after purchasing an additional 30,420 shares during the period. Deep Track Capital LP lifted its holdings in ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock worth $35,879,000 after purchasing an additional 144,214 shares during the last quarter. Finally, Global Alpha Capital Management Ltd. boosted its stake in ANI Pharmaceuticals by 16.4% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after purchasing an additional 88,100 shares during the period. Institutional investors own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ANIP shares. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 target price on the stock. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.